Tolebrutinib – complimentary MARA Rating report: pricing & reimbursement risk assessment for secondary progressive multiple sclerosis.
This complimentary MARA Rating® report examines Tolebrutinib’s market-access risk profile for treating non-relapsing secondary progressive multiple sclerosis (SPMS). The therapy received a MARA Score of 2.25 out of 4, corresponding to a Very Weak (B+) rating. Compared with benchmarks, the neurology 5-year average is 2.9 and the broader industry average is 3.0, placing Tolebrutinib well below both standards.
Clinical Effectiveness: B++ (Marginal)
In relapsing MS, Tolebrutinib showed similar efficacy to existing therapies, failing to outperform teriflunomide in relapse reduction. However, in non-relapsing SPMS it demonstrated significant slowing of disability progression – a meaningful advance in a patient group with limited options. While not superior in relapsing MS, it provides unique clinical value in an underserved population.
Comparator Selection: A++ (Excellent)
Trial designs used teriflunomide as an active comparator for relapsing MS, aligning with clinical guidelines. For non-relapsing SPMS, placebo was used where no approved therapies exist. These choices were appropriate and relevant to current standards, lending credibility to the findings.
Care-Pathway Integration: A+ (Very Strong)
Tolebrutinib can be introduced into existing treatment structures without significant changes or new diagnostics. Monitoring requirements remain consistent with current MS practices, ensuring smooth integration into healthcare delivery.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk – clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more – each scored on a seven-level scale (A++ to C).
We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains – Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty – available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email sales@mararating.com to learn more and unlock your access.
Access this report and hundreds of others: https://mararating.com/mara-ratings-list
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer at mararating.com.